Table 3.
Therapeutic effects on mutant RAS
| Regimen | n | RR (%) | PFS (M) | HR | OS (M) | HR | |
|---|---|---|---|---|---|---|---|
| PRIME | FOLFOX4 | 276 | — | 8.7 | HR 1.31 (P = 0.008) | 19.2 | HR 1.25 (P = 0.034) |
| FOLFOX4 + Pmab | 272 | — | 7.3 | 15.6 | |||
| 20050181 | FOLFIRI | 294 | 13 | 4.0 | HR 0.861 (P = 0.14) | 11.1 | HR 0.914 (P = 0.34) |
| FOLFIRI + Pmab | 299 | 15 | 4.8 | 11.8 | |||
| 20020408 | BSC | 114 | 0 | 7.3 weeks | HR 0.97 (P = 0.729) | — | — |
| BSC+Pmab | 99 | 1 | 7.4 weeks | — | |||
| OPUS | FOLFOX4 | 75 | 50.7 | 7.8 | HR 1.54 (P = 0.0309) | 17.8 | HR 1.29 (P = 0.1573) |
| FOLFOX4+Cmab | 92 | 37.0 | 5.6 | 13.5 | |||
| CRYSTAL | FOLFIRI | 214 | 36.0 | 7.5 | HR 1.10 (P = 0.47) | 17.7 | HR 1.05 (P = 0.64) |
| FOLFIRI+Cmab | 246 | 31.7 | 7.4 | 16.4 | |||
| FIRE-3 | FOLFIRI+Bev | 86 | 51.2 | 10.1 | HR 1.31 (P = 0.085) | 20.6 | HR 1.09 (P = 0.60) |
| FOLFIRI+Cmab | 171 | 65.5 | 10.4 | 33.1 |
Bev, bevacizumab; Cmab, cetuximab; HR, hazard ratio; OS, overall survival; PFS, progression free survival; Pmab, panitumumab; RR, response rate.